Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy + neoadjuvant chemotherapy + cardonilizumab in operable locally advanced head and neck squamous cell carcinoma (Phase II)
ChiCTR2400084430Phase 2Recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in head and neck squamous cell carcinoma (HNSCC) and oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Dongguan People's Hospital. Primary endpoint: Complete pathological response rate (pCR). Started May 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on ChiCTR2400084430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084430.